These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported||2009-011099-31||A Multi-center, Randomized, Double-blind, Comparator-controlled, Dose-escalation Safety Assessment Study of Combination Treatment with IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 ...||2011-01-14||due-trials|
|Not reported Terminated||2010-021963-34||A Phase 2, Randomized, Double-Blind, Comparator-Controlled, 12-week Trial of IMO-2125 plus Ribavirin in Patients Infected with Hepatitis C Virus who were Nonresponders to Pegylated-Interferon plus Rib...||2011-02-04||due-trials|
|Not reported Terminated||2011-000091-33||A Phase 2, Randomized, Double-Blind, Comparator-Controlled, 12-week Trial of IMO-2125 plus Ribavirin in Treatment-Naive Patients Infected with Hepatitis C Virus, Genotype 1||2012-01-20||due-trials|
|Completed, but no date||2013-000164-28||A Randomized, Double-Blind, Placebo-Controlled, 12-week Dose-Ranging Trial of IMO-8400 in Patients with Moderate to Severe||bad-data|
|Not reported||2015-003277-15||A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis||2018-04-04||due-trials|
|Other||2017-002454-36||A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma||not-yet-due|
|Completed, report not yet due Terminated||2018-003690-10||Study of Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors||2019-10-14||not-yet-due|